David Baltimore is a world-renowned biologist who in 1975 won the Nobel Prize in physiology or medicine along with Howard Temin and Renato Dulbecco “for their discoveries concerning the interaction between tumor viruses and the genetic material of the cell.” We had the chance to sit down and discuss science, cancer research, and more with…
In the second installment of the “My Story” series, Friends President & CEO, Jeff Allen, PhD, recounts his personal experience with cancer from a young age when his grandfather was sick with the disease and why he is motivated for working in this field. With a background in cancer research focused upon molecular changes associated with cancer…
From L-R: Dr. Gregory Reaman, Pr. Gilles Vassal, Mr. Raymond Rodriguez-Torres Oncology is a widely studied and researched field, and the advancements in scientific and clinical understanding of pediatric oncology provides an opportunity to better inform pediatric drug development. For a long time, there was an idea that children are “tiny adults” and…
A Note from Joel S. Marcus, Co-Founder, Alexandria Summit; Chairman, Chief Executive Officer & Co-Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments; Lynne Zydowsky, PhD, Co-Founder, Alexandria Summit; Chief Science Advisor to the CEO, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments; and Ellen Sigal, PhD, Chair and Founder of Friends of Cancer Research: Since 2011,…
Margaret Hamburg has been the Commissioner of the Food and Drug Administration (FDA) since 2009. In the below entry, part 2 of 2, Dr. Hamburg discusses her experience as Commissioner, her perspective on the FDA, and her advice for future FDA Commissioners. The interview was conducted by Ryan Hohman, Managing Director, Policy & Public Affairs of Friends…
Margaret Hamburg has been the Commissioner of the Food and Drug Administration (FDA) since 2009. In the below entry, part 1 of 2, Dr. Hamburg discusses critical issues in FDA drug policy, including the use of surrogate endpoints and the development of new regulatory tools. The interview was conducted by Ryan Hohman, Managing Director, Policy &…
In Engaging Innovation‘s inaugural conversation, Dr. Francis Collins, Director of the National Institutes of Health (NIH), started a dynamic dialogue which touched on some of the most important topics in science and research. As part of this conversation, Dr. Collins emphasized the critical role public-private partnerships play in advancing biomedical research, calling them an “absolute essential priority” to…
